Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer’s disease: preclinical proof of concept
Open accessThe DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
Microglia significantly contribute to the pathophysiology of Alzheimer's disease but an effective microglia-targeted therapeutic approach is not yet available clinically. The potassium channels Kv1.3 and Kir2.1 play important roles in regulating immune cell functions and have been implicated by in vitro studies in the 'M1-like pro-inflammatory' or 'M2-like anti-inflammatory' state of microglia, respectively. We here found that amyloid-β oligomer-induced expression of Kv1.3 and Kir2.1 in cultured primary microglia. Likewise, ex vivo microglia acutely isolated from the Alzheimer's model 5xFAD mice co-expressed Kv1.3 and Kir2.1 as well as markers traditionally associated with M1 and M2 activation suggesting that amyloid-β oligomer induces a microglial activation state that is more complex than previously thought. Using the orally available, brain penetrant small molecule Kv1.3 blocker PAP-1 as a tool, we showed that pro-inflammatory and neurotoxic microglial responses induced by amyloid-β oligomer required Kv1.3 activity in vitro and in hippocampal slices. Since we further observed that Kv1.3 was highly expressed in microglia of transgenic Alzheimer's mouse models and human Alzheimer's disease brains, we hypothesized that pharmacological Kv1.3 inhibition could mitigate the pathology induced by amyloid-β aggregates. Indeed, treating APP/PS1 transgenic mice with a 5-month oral regimen of PAP-1, starting at 9 months of age, when the animals already manifest cognitive deficits and amyloid pathology, reduced neuroinflammation, decreased cerebral amyloid load, enhanced hippocampal neuronal plasticity, and improved behavioural deficits. The observed decrease in cerebral amyloid deposition was consistent with the in vitro finding that PAP-1 enhanced amyloid-β uptake by microglia. Collectively, these results provide proof-of-concept data to advance Kv1.3 blockers to Alzheimer's disease clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Kv1.3 channels are highly expressed by pro-inflammatory microglia in mouse models of refractory seizures as well as radiation neurotoxicity and recently, Kv1.3 blockade by Pap1 was shown to have amyloid-lowering and neuroprotective effects in AD mouse models [26, 48, 49, 51, 62, 63].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Kv1.3 channels are highly expressed by pro-inflammatory microglia in mouse models of refractory seizures as well as radiation neurotoxicity and recently, Kv1.3 blockade by Pap1 was shown to have amyloid-lowering and neuroprotective effects in AD mouse models [26, 48, 49, 51, 62, 63].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [49]
In the citing paper
“Kv1.3 channel blockade by the small molecule Pap1 was also found to mitigate Aβ deposition and improve neurobehavioral measures in AD mouse models [49].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Macrophage activation and polarization: nomenclature and experimental guidelines
Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.008 · Cited by 6,337 · cited 2×
“immune system, which acquire stable phenotypes after subtype differentiation or class-switching, cells of the innate immune system such as microglia are highly plastic and typically do not acquire a stable phenotype that can be readily categorized by specific markers or signature genes (Murray et al., 2014; Bohlen et…”
BackgroundNeuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 2×
“A gen- erally accepted hypothesis states that activated microglia re- lease cytotoxic substances and pro-inflammatory cytokines that cause neuronal damage and aggravate Alzheimer’s dis- ease pathology (Heneka et al., 2015).”
BackgroundThe amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“Several key conclusions can be drawn from our study: (i) soluble AbO, the highly toxic amyloid-b species implicated as one of the principal initiators of Alzheimer’s disease phenotypes (Selkoe and Hardy, 2016), enhances microglial Kv1.”
BackgroundStructural and functional features of central nervous system lymphatic vessels
Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., Derecki, N. C., Castle, D., Mandell, J. W., Lee, K. S., et al. (2015) · Nature · doi:10.1038/nature14432 · Cited by 4,413
Kettenmann, H., Hanisch, U.-K., Noda, M., & Verkhratsky, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00011.2010 · Cited by 3,547 · cited 2×
“1, another K + channel often expressed in myeloid cells and involved in regulating their function (Kettenmann et al., 2011; Feske et al., 2015), was highly upregulated (Nguyen et al.”
BackgroundOakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 2×
“Alzheimer’s mouse model 5xFAD (Oakley et al., 2006), in which AbO is the major toxic amyloid-b species able to”
BackgroundMethodDiffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · cited 2×
“Production and administration of amyloid-b oligomer Amyloid-b oligomer (AbO) was prepared following a standard procedure (Lambert et al., 1998) except that the amyloid-b1-42 peptide (Bachem) was diluted with Opti-MEM culture medium instead of the F12 medium originally described, before incubation…”
MethodNLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898 · cited 3×
“…form part of the age-related changes in microglial function, documented by several lines of investigation, such as altered responses to amyloid-b aggregates or downregulation of ‘sensome’ genes (Hickman et al., 2008, 2013; Cameron et al., 2012; Heneka et al., 2013; Johansson et al., 2015).”
BackgroundIntegrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease
Zhang, B., Gaiteri, C., Bodea, L.-G., Wang, Z., McElwee, J., Podtelezhnikov, A. A., Zhang, C., Xie, T., Tran, L., Dobrin, R., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.030 · Cited by 1,657 · cited 2×
“A network-based analysis of whole-genome gene-expression profiling and genotypic data obtained from 1647 Alzheimer’s disease and non-demented brain samples highlighted the immune/ microglia module as the molecular system most strongly associated with the pathophysiology of Alzheimer’s disease (Zhang et al., 2013).”
BackgroundMethodJankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575 · cited 1×
“Similar results were obtained using the other Alzheimer’s transgenic model called APP/PS1 (Jankowsky et al., 2004) (Supplementary Fig.”
ResultA polarizing question: do M1 and M2 microglia exist?
Ransohoff, R. M. (2016) · Nature Neuroscience · doi:10.1038/nn.4338 · Cited by 1,573 · cited 2×
“…cells responding to traumatic brain injury concurrently adopted both inflammatory and reparative features with a lack of exclusivity (Kim et al., 2016; Ransohoff, 2016) and suggests that AbO-treated microglia adopted an activation state that is more complex than simply being ‘pro-inflammatory’ or…”
BackgroundThe microglial sensome revealed by direct RNA sequencing
Hickman, S. E., Kingery, N. D., Ohsumi, T. K., Borowsky, M. L., Wang, L.-C., Means, T. K., & El Khoury, J. (2013) · Nature Neuroscience · doi:10.1038/nn.3554 · Cited by 1,511 · cited 1×
“…form part of the age-related changes in microglial function, documented by several lines of investigation, such as altered responses to amyloid-b aggregates or downregulation of ‘sensome’ genes (Hickman et al., 2008, 2013; Cameron et al., 2012; Heneka et al., 2013; Johansson et al., 2015).”
BackgroundMicroglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329 · cited 5×
“In our experiments, PAP-1 was administered to APP/PS1 mice at an age when microglia amyloid-b clearance capacity was impaired (Hickman et al., 2008).”
BackgroundMethodInfluentialYoung blood reverses age-related impairments in cognitive function and synaptic plasticity in mice
Villeda, S. A., Plambeck, K. E., Middeldorp, J., Castellano, J. M., Mosher, K. I., Luo, J., Smith, L. K., Bieri, G., Lin, K., Berdnik, D., et al. (2014) · Nature Medicine · doi:10.1038/nm.3569 · Cited by 1,081 · cited 1×
“Peripheral immune modulation may impact neuroinflammation or brain function via humoral or cellu- lar factors (Villeda et al., 2014; Prinz and Priller, 2017).”
BackgroundEl Khoury, J., Toft, M., Hickman, S. E., Means, T. K., Terada, K., Geula, C., & Luster, A. D. (2007) · Nature Medicine · doi:10.1038/nm1555 · Cited by 915
Voltage-gated potassium channels as therapeutic targets
Wulff, H., Castle, N. A., & Pardo, L. A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2983 · Cited by 799 · cited 2×
“3 is regarded as a relatively safe drug target (Wulff et al., 2009).”
BackgroundSelf-citationIon Channels in Innate and Adaptive Immunity
Feske, S., Wulff, H., & Skolnik, E. Y. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112212 · Cited by 768 · cited 3×
“3 plays an important role in immune cell activation by modulating Ca2 + signalling (Wulff et al., 2007; Feske et al., 2015).”
BackgroundSelf-citationScavenger receptor-mediated adhesion of microglia to β-amyloid fibrils
Khoury, J. E., Hickman, S. E., Thomas, C. A., Cao, L., Silverstein, S. C., & Loike, J. D. (1996) · Nature · doi:10.1038/382716a0 · Cited by 727
Spangenberg, E. E., Lee, R. J., Najafi, A. R., Rice, R. A., Elmore, M. R. P., Blurton-Jones, M., West, B. L., & Green, K. N. (2016) · Brain · doi:10.1093/brain/aww016 · Cited by 695 · cited 1×
“…Johansson et al., 2015; Krauthausen et al., 2015), but appears contradictory to reports showing that inducible microglia depletion by gen- etic or pharmacological means fails to affect amyloid path- ology in transgenic Alzheimer’s disease models (Grathwohl et al., 2009; Spangenberg et al., 2016).”
ResultJay, T. R., Miller, C. M., Cheng, P. J., Graham, L. C., Bemiller, S., Broihier, M. L., Xu, G., Margevicius, D., Karlo, J. C., Sousa, G. L., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20142322 · Cited by 682 · cited 1×
“…immune cells into the brain in Alzheimer’s dis- ease mouse models or in human Alzheimer’s disease brains (Bien-Ly et al., 2015; Prinz and Priller, 2017), many brain mononuclear phagocytes that surround amyloid-b plaques are CD45high, suggesting their peripheral monocyte origin (Jay et al., 2015).”
BackgroundBohlen, C. J., Bennett, F. C., Tucker, A. F., Collins, H. Y., Mulinyawe, S. B., & Barres, B. A. (2017) · Neuron · doi:10.1016/j.neuron.2017.04.043 · Cited by 658 · cited 1×
“…phenotypes after sub- type differentiation or class-switching, cells of the innate immune system such as microglia are highly plastic and typically do not acquire a stable phenotype that can be readily categorized by specific markers or signature genes (Murray et al., 2014; Bohlen et al., 2017).”
BackgroundThe role of peripheral immune cells in the CNS in steady state and disease
Prinz, M., & Priller, J. (2017) · Nature Neuroscience · doi:10.1038/nn.4475 · Cited by 657 · cited 2×
“Peripheral immune modulation may impact neuroinflammation or brain function via humoral or cellu- lar factors (Villeda et al., 2014; Prinz and Priller, 2017).”
BackgroundKv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases
Beeton, C., Wulff, H., Standifer, N. E., Azam, P., Mullen, K. M., Pennington, M. W., Kolski-Andreaco, A., Wei, E., Grino, A., Counts, D. R., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605136103 · Cited by 538 · cited 4×
“3 blocker PAP-1 [5-(4-phenoxybutoxy)psoralen; Schmitz et al., 2005] and demonstrated that this small molecule ef- fectively prevents autoimmune diabetes in a rat model and treats psoriasis in a humanized xenograft model in mice (Beeton et al., 2006; Kundu-Raychaudhuri et al., 2014).”
BackgroundInfluentialSelf-citationSeyfried, N. T., Dammer, E. B., Swarup, V., Nandakumar, D., Duong, D. M., Yin, L., Deng, Q., Nguyen, T., Hales, C. M., Wingo, T., et al. (2017) · Cell Systems · doi:10.1016/j.cels.2016.11.006 · Cited by 477 · cited 1×
“An even stronger correlation was re- cently found between a similar immune/microglial module and Alzheimer’s disease with large-scale protein co-expres- sion network analysis (Seyfried et al., 2017).”
BackgroundSelf-citationAlzheimer’s Disease Genetics: From the Bench to the Clinic
Karch, C. M., Cruchaga, C., & Goate, A. M. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.041 · Cited by 473 · cited 2×
“Immune recep- tor genes expressed in microglia or myeloid cells, such as TREM2 and CD33, are among the few genes that impose moderate risk for the development of Alzheimer’s disease (Karch et al., 2014).”
BackgroundK+ channels as targets for specific immunomodulation
George Chandy, K., Wulff, H., Beeton, C., Pennington, M., Gutman, G. A., & Cahalan, M. D. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.03.010 · Cited by 427 · cited 1×
“3 homotetramers found in T cells, microglia and macrophages (Chandy et al., 2004; Wulff et al., 2009).”
BackgroundSelf-citationCapiralla, H., Vingtdeux, V., Zhao, H., Sankowski, R., Al‐Abed, Y., Davies, P., & Marambaud, P. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07594.x · Cited by 426 · cited 1×
“Amyloid-b aggregates, including AbO, stimulate microglia in part via a well-known LPS receptor, TLR4 (Toll-like receptor 4) (Capiralla et al., 2012; Ledo et al., 2016), and induce responses widely considered as pro-inflammatory.”
BackgroundThe voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS
Wulff, H., Calabresi, P. A., Allie, R., Yun, S., Pennington, M., Beeton, C., & Chandy, K. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16921 · Cited by 422 · cited 2×
“3 (Wulff et al., 2003; Feske et al., 2015).”
Self-citationGriffin, M. O., Fricovsky, E., Ceballos, G., & Villarreal, F. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00047.2010 · Cited by 413 · cited 1×
“However, the microglial contribution to hippocampal LTP is by no means conclusive in view of the pleotropic, non-microglial effects of minocycline (Griffin et al., 2010).”
BackgroundFormation and maintenance of Alzheimer's disease β-amyloid plaques in the absence of microglia
Grathwohl, S. A., Kälin, R. E., Bolmont, T., Prokop, S., Winkelmann, G., Kaeser, S. A., Odenthal, J., Radde, R., Eldh, T., Gandy, S., et al. (2009) · Nature Neuroscience · doi:10.1038/nn.2432 · Cited by 401 · cited 1×
“…Johansson et al., 2015; Krauthausen et al., 2015), but appears contradictory to reports showing that inducible microglia depletion by gen- etic or pharmacological means fails to affect amyloid path- ology in transgenic Alzheimer’s disease models (Grathwohl et al., 2009; Spangenberg et al., 2016).”
ResultIl10 Deficiency Rebalances Innate Immunity to Mitigate Alzheimer-Like Pathology
Guillot-Sestier, M.-V., Doty, K. R., Gate, D., Rodriguez, J., Leung, B. P., Rezai-Zadeh, K., & Town, T. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.068 · Cited by 363 · cited 2×
“…specific microglial signalling pathways alters amyloid-b deposition and clearance (El Khoury et al., 2007; Cameron et al., 2012; Heneka et al., 2013; Guillot-Sestier et al., 2015; Hellwig et al., 2015; Johansson et al., 2015; Krauthausen et al., 2015), but appears contradictory to reports showing…”
BackgroundGarcia-Calvo, M., Leonard, R. J., Novick, J., Stevens, S. P., Schmalhofer, W., Kaczorowski, G. J., & Garcia, M. L. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)46707-x · Cited by 345 · cited 1×
“3 specific blockers ShK-186 (Tarcha et al., 2012), margatoxin (MgTX; Garciacalvo et al., 1993), and PAP-1 (Fig.”
Maezawa, I., Zimin, P. I., Wulff, H., & Jin, L.-W. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.135244 · Cited by 278 · cited 11×
“and activity in AbO-stimulated microglia We previously showed that AbO, composed of amyloid-b1-42 peptide, at low (5–200) nanomolar concentrations is a robust microglia activator (Maezawa et al., 2011).”
BackgroundMethodInfluentialSelf-citationItagaki, S., McGeer, P. L., & Akiyama, H. (1988) · Neuroscience Letters · doi:10.1016/0304-3940(88)90690-8 · Cited by 271 · cited 1×
“Several groups also reported the presence of T cells in the brain of Alzheimer’s disease patients (Itagaki et al., 1988; Town et al., 2005; Bryson and Lynch, 2016).”
BackgroundZaritsky, J. J., Redell, J. B., Tempel, B. L., & Schwarz, T. L. (2001) · The Journal of Physiology · doi:10.1111/j.1469-7793.2001.t01-1-00697.x · Cited by 244 · cited 2×
“1 plays a vital role in the vasculature and in cardiac excitability; its knockout causes mice to die within hours after birth (Zaritsky et al., 2001).”
BackgroundCongo red and thioflavin‐T analogs detect Aβ oligomers
Maezawa, I., Hong, H., Liu, R., Wu, C., Cheng, R. H., Kung, M., Kung, H. F., Lam, K. S., Oddo, S., LaFerla, F. M., et al. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04972.x · Cited by 227 · cited 2×
“Our preparation has been extensively characterized (Maezawa et al., 2006, 2008).”
MethodSelf-citationSchmitz, A., Sankaranarayanan, A., Azam, P., Schmidt-Lassen, K., Homerick, D., Hänsel, W., & Wulff, H. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.015669 · Cited by 226 · cited 2×
“3 blocker PAP-1 [5-(4-phenoxybutoxy)psoralen; Schmitz et al., 2005] and demonstrated that this small molecule ef- fectively prevents autoimmune diabetes in a rat model and treats psoriasis in a humanized xenograft model in mice (Beeton et al., 2006; Kundu-Raychaudhuri et al., 2014).”
BackgroundSelf-citationWulff, H., Kolski-Andreaco, A., Sankaranarayanan, A., Sabatier, J.-M., & Shakkottai, V. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707780831186 · Cited by 218 · cited 2×
“3 plays an important role in immune cell activation by modulating Ca2 + signalling (Wulff et al., 2007; Feske et al., 2015).”
BackgroundSelf-citationMicroglia Kv1.3 Channels Contribute to Their Ability to Kill Neurons
Fordyce, C. B., Jagasia, R., Zhu, X., & Schlichter, L. C. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1251-05.2005 · Cited by 213 · cited 2×
“3 blockers have been demonstrated to inhibit microglia- mediated neurotoxicity in culture (Fordyce et al., 2005) and to protect mice from microglia-mediated radiation- induced brain injury in vivo (Peng et al., 2014).”
BackgroundLack of Widespread BBB Disruption in Alzheimer’s Disease Models: Focus on Therapeutic Antibodies
Bien-Ly, N., Boswell, C. A., Jeet, S., Beach, T. G., Hoyte, K., Luk, W., Shihadeh, V., Ulufatu, S., Foreman, O., Lu, Y., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.09.036 · Cited by 198 · cited 1×
“…whether there is an influx of peripheral immune cells into the brain in Alzheimer’s dis- ease mouse models or in human Alzheimer’s disease brains (Bien-Ly et al., 2015; Prinz and Priller, 2017), many brain mononuclear phagocytes that surround amyloid-b plaques are CD45high, suggesting their…”
BackgroundMatheu, M. P., Beeton, C., Garcia, A., Chi, V., Rangaraju, S., Safrina, O., Monaghan, K., Uemura, M. I., Li, D., Pal, S., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.07.015 · Cited by 196 · cited 2×
“3 inhibitors are ‘mild’ immunosuppressants and do not affect the ability of rodents or primates to clear bacterial or viral infections (Pereira et al., 2007; Matheu et al., 2008).”
BackgroundSelf-citationWulff, H., Knaus, H.-G., Pennington, M., & Chandy, K. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.776 · Cited by 194 · cited 1×
“1 channel (Wulff et al., 2003, 2004; Beeton et al., 2006).”
Self-citationWang, Q., Rowan, M. J., & Anwyl, R. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0233-04.2004 · Cited by 193 · cited 2×
“…reported that minocycline, a tetracycline inhibitor of microglial activation, and inducible nitric oxide synthase (iNOS) reduction, prevented hippocampal LTP disruption by amyloid-b (Wang et al., 2004), suggesting that microglial activation and NO production contribute to amyloid-b synaptotoxicity.”
BackgroundMethodT-Cells in Alzheimer's Disease
Town, T., Tan, J., Flavell, R. A., & Mullan, M. (2005) · NeuroMolecular Medicine · doi:10.1385/nmm:7:3:255 · Cited by 183 · cited 1×
“Several groups also reported the presence of T cells in the brain of Alzheimer’s disease patients (Itagaki et al., 1988; Town et al., 2005; Bryson and Lynch, 2016).”
BackgroundFadool, D. A., Tucker, K., Perkins, R., Fasciani, G., Thompson, R. N., Parsons, A. D., Overton, J. M., Koni, P. A., Flavell, R. A., & Kaczmarek, L. K. (2004) · Neuron · doi:10.1016/s0896-6273(03)00844-4 · Cited by 178
Nguyen, H. M., Grössinger, E. M., Horiuchi, M., Davis, K. W., Jin, L., Maezawa, I., & Wulff, H. (2017) · Glia · doi:10.1002/glia.23078 · Cited by 178 · cited 10×
“Electrophysiology on cultured and acutely isolated microglia Whole-cell patch-clamp experiments on cultured or acutely isolated microglia were performed as previously described (Chen et al., 2016; Nguyen et al., 2017).”
BackgroundMethodInfluentialSelf-citationTarcha, E. J., Olsen, C. M., Probst, P., Peckham, D., Muñoz-Elías, E. J., Kruger, J. G., & Iadonato, S. P. (2017) · PLOS ONE · doi:10.1371/journal.pone.0180762 · Cited by 167 · cited 1×
“PAP-1 has further completed IND (Investigational New Drug)- enabling toxicity studies, while ShK-186 has passed both IND toxicity studies and phase 1 safety studies without any adverse findings and has demonstrated efficacy in a small phase 1b study in plaque psoriasis (Tarcha et al., 2017).”
BackgroundConformation‐Dependent Anti‐Amyloid Oligomer Antibodies
Kayed, R., & Glabe, C. G. (2006) · Methods in Enzymology · doi:10.1016/s0076-6879(06)13017-7 · Cited by 166 · cited 1×
“604 | BRAIN 2018: 141; 596–612 I. Maezawa et al. et al., 2008) or an AbO-specific antibody A11 (Kayed and Glabe, 2006) (Fig.”
Prostaglandin signaling suppresses beneficial microglial function in Alzheimer’s disease models
Johansson, J. U., Woodling, N. S., Wang, Q., Panchal, M., Liang, X., Trueba-Saiz, A., Brown, H. D., Mhatre, S. D., Loui, T., & Andreasson, K. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77487 · Cited by 161 · cited 2×
“…form part of the age-related changes in microglial function, documented by several lines of investigation, such as altered responses to amyloid-b aggregates or downregulation of ‘sensome’ genes (Hickman et al., 2008, 2013; Cameron et al., 2012; Heneka et al., 2013; Johansson et al., 2015).”
BackgroundBrain trauma elicits non-canonical macrophage activation states
Kim, C. C., Nakamura, M. C., & Hsieh, C. L. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0581-z · Cited by 149 · cited 2×
“This result is consistent with a previous single-cell gene expression study showing that individual myeloid cells responding to traumatic brain injury concurrently adopted both inflammatory and reparative features with a lack of exclusivity (Kim et al., 2016; Ransohoff, 2016) and suggests that AbO-treated microglia ad…”
BackgroundResultCXCR3 promotes plaque formation and behavioral deficits in an Alzheimer’s disease model
Krauthausen, M., Kummer, M. P., Zimmermann, J., Reyes-Irisarri, E., Terwel, D., Bulic, B., Heneka, M. T., & Müller, M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci66771 · Cited by 147 · cited 2×
“Our result is consistent with several reports showing that selective modulation of specific microglial signalling pathways alters amyloid-b deposition and clearance (El Khoury et al., 2007; Cameron et al., 2012; Heneka et al., 2013; Guillot-Sestier et al., 2015; Hellwig et al., 2015; Johansson et al., 2015; Krauthause…”
BackgroundResultLedo, J. H., Azevedo, E. P., Beckman, D., Ribeiro, F. C., Santos, L. E., Razolli, D. S., Kincheski, G. C., Melo, H. M., Bellio, M., Teixeira, A. L., et al. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1269-16.2016 · Cited by 138 · cited 2×
“Amyloid-b aggregates, including AbO, stimulate microglia in part via a well-known LPS receptor, TLR4 (Toll-like receptor 4) (Capiralla et al., 2012; Ledo et al., 2016), and induce responses widely considered as pro-inflammatory.”
BackgroundPotassium Channel Kv1.3 Is Highly Expressed by Microglia in Human Alzheimer's Disease
Rangaraju, S., Gearing, M., Jin, L.-W., & Levey, A. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141704 · Cited by 137 · cited 5×
“3 is typically expressed highest in microglia in the brain (Rangaraju et al., 2015).”
BackgroundMethodInfluentialSelf-citationTarcha, E. J., Chi, V., Muñoz-Elías, E. J., Bailey, D., Londono, L. M., Upadhyay, S. K., Norton, K., Banks, A., Tjong, I., Nguyen, H., et al. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.191890 · Cited by 117 · cited 5×
“3 specific blockers ShK-186 (Tarcha et al., 2012), margatoxin (MgTX; Garciacalvo et al., 1993), and PAP-1 (Fig.”
BackgroundInfluentialSelf-citationChen, Y.-J., Nguyen, H. M., Maezawa, I., Grössinger, E. M., Garing, A. L., Köhler, R., Jin, L.-W., & Wulff, H. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x15611434 · Cited by 106 · cited 2×
“3 expression in microglia acutely isolated from the infarct areas of mice subjected to experimental stroke (Chen et al., 2016).”
BackgroundMethodSelf-citationWang, H., Wu, M., Yu, H., Long, S., Stevens, A., Engers, D. W., Sackin, H., Daniels, J. S., Dawson, E. S., Hopkins, C. R., et al. (2011) · ACS Chemical Biology · doi:10.1021/cb200146a · Cited by 101 · cited 1×
“1 inhibitors, high micromolar to millimolar Ba2 + or the small molecule ML133 (IC50 2 mM) (Wang et al., 2011), are both unsuitable for in vivo use and are even problematic in experiments with cultured microglia because of their high toxicity (Nguyen et al., 2017).”
BackgroundThe Inflammatory Response in Alzheimer's Disease
Rogers, J. (2008) · Journal of Periodontology · doi:10.1902/jop.2008.080171 · Cited by 92
Hellwig, S., Masuch, A., Nestel, S., Katzmarski, N., Meyer-Luehmann, M., & Biber, K. (2015) · Scientific Reports · doi:10.1038/srep14624 · Cited by 91 · cited 2×
“…pathways alters amyloid-b deposition and clearance (El Khoury et al., 2007; Cameron et al., 2012; Heneka et al., 2013; Guillot-Sestier et al., 2015; Hellwig et al., 2015; Johansson et al., 2015; Krauthausen et al., 2015), but appears contradictory to reports showing that inducible microglia…”
BackgroundMaezawa, I., Hong, H., Wu, H., Battina, S. K., Rana, S., Iwamoto, T., Radke, G. A., Pettersson, E., Martin, G. M., Hua, D. H., et al. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03862.x · Cited by 88 · cited 2×
“Our preparation has been extensively characterized (Maezawa et al., 2006, 2008).”
MethodSelf-citationJin, L.-W., Horiuchi, M., Wulff, H., Liu, X.-B., Cortopassi, G. A., Erickson, J. D., & Maezawa, I. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2778-14.2015 · Cited by 88 · cited 2×
“Microglia were acutely isolated from adult brains without culturing as described (Jin et al., 2015).”
MethodSelf-citationGo, M., Kou, J., Lim, J.-E., Yang, J., & Fukuchi, K.-I. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.09.073 · Cited by 88 · cited 1×
“3 blockers as attractive therapeutic agents to mitigate amyloid-b-induced pro-inflammatory microglial responses that are highly relevant to Alzheimer’s disease pathogenesis (Go et al., 2016; Ledo et al., 2016; Rangaraju et al., 2017).”
BackgroundCompensatory Anion Currents in Kv1.3 Channel-deficient Thymocytes
Koni, P. A., Khanna, R., Chang, M. C., Tang, M. D., Kaczmarek, L. K., Schlichter, L. C., & Flavell, R. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304879200 · Cited by 87 · cited 2×
“3 / mice are viable, reproduce normally and exhibit very subtle phenotypes (Koni et al., 2003; Fadool et al., 2004).”
BackgroundTan, M.-S., Yu, J.-T., Jiang, T., Zhu, X.-C., Guan, H.-S., & Tan, L. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-131148 · Cited by 79
Blockade of Kv1.3 channels ameliorates radiation-induced brain injury
Peng, Y., Lu, K., Li, Z., Zhao, Y., Wang, Y., Hu, B., Xu, P., Shi, X., Zhou, B., Pennington, M., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not221 · Cited by 78 · cited 1×
“3 blockers have been demonstrated to inhibit microglia- mediated neurotoxicity in culture (Fordyce et al., 2005) and to protect mice from microglia-mediated radiation- induced brain injury in vivo (Peng et al., 2014).”
BackgroundRangaraju, S., Raza, S. A., Pennati, A., Deng, Q., Dammer, E. B., Duong, D., Pennington, M. W., Tansey, M. G., Lah, J. J., Betarbet, R., et al. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0906-6 · Cited by 75 · cited 2×
“3 in pro-inflammatory microglial activation (Rangaraju et al., 2017) while electrophysiological studies by our group demonstrated upregulated Kv1.”
BackgroundSelf-citationCameron, B., Tse, W., Lamb, R., Li, X., Lamb, B. T., & Landreth, G. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1729-12.2012 · Cited by 73 · cited 3×
“…form part of the age-related changes in microglial function, documented by several lines of investigation, such as altered responses to amyloid-b aggregates or downregulation of ‘sensome’ genes (Hickman et al., 2008, 2013; Cameron et al., 2012; Heneka et al., 2013; Johansson et al., 2015).”
BackgroundKundu-Raychaudhuri, S., Chen, Y.-J., Wulff, H., & Raychaudhuri, S. P. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.07.003 · Cited by 73 · cited 2×
“3 blocker PAP-1 [5-(4-phenoxybutoxy)psoralen; Schmitz et al., 2005] and demonstrated that this small molecule ef- fectively prevents autoimmune diabetes in a rat model and treats psoriasis in a humanized xenograft model in mice (Beeton et al., 2006; Kundu-Raychaudhuri et al., 2014).”
BackgroundSelf-citationInhibition of Alzheimer’s amyloid toxicity with a tricyclic pyrone molecule in vitro and in vivo
Hong, H., Rana, S., Barrigan, L., Shi, A., Zhang, Y., Zhou, F., Jin, L., & Hua, D. H. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05866.x · Cited by 67 · cited 1×
“…from the widely used 600 | BRAIN 2018: 141; 596–612 I. Maezawa et al. Alzheimer’s mouse model 5xFAD (Oakley et al., 2006), in which AbO is the major toxic amyloid-b species able to activate microglia to contribute to neuroinflammation (Hong et al., 2009; Xiao et al., 2013; Heneka et al., 2015).”
BackgroundSelf-citationHong, H., Maezawa, I., Yao, N., Xu, B., Díaz-Avalos, R., Rana, S., Hua, D. H., Cheng, R. H., Lam, K. S., & Jin, L. (2006) · Brain Research · doi:10.1016/j.brainres.2006.10.093 · Cited by 65 · cited 1×
“…imaged using atomic force microscopy to characterize the size and shape of the aggregates, and the biological activities were confirmed by determining AbO’s neurotoxic activity and ability to rapidly induce exocytosis of MTT formazan, as described (Maezawa et al., 2006, 2008; Hong et al., 2007).”
MethodSelf-citationXiao, C., Davis, F. J., Chauhan, B. C., Viola, K. L., Lacor, P. N., Velasco, P. T., Klein, W. L., & Chauhan, N. B. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-122419 · Cited by 59 · cited 1×
“…from the widely used 600 | BRAIN 2018: 141; 596–612 I. Maezawa et al. Alzheimer’s mouse model 5xFAD (Oakley et al., 2006), in which AbO is the major toxic amyloid-b species able to activate microglia to contribute to neuroinflammation (Hong et al., 2009; Xiao et al., 2013; Heneka et al., 2015).”
BackgroundHelms, L. M. H., Felix, J. P., Bugianesi, R. M., García, M. L., Stevens, S., Leonard, R. J., Knaus, H., Koch, R., Wanner, S. G., Kaczorowski, G. J., et al. (1997) · Biochemistry · doi:10.1021/bi962351p · Cited by 49 · cited 1×
“6 subunits (Helms et al., 1997) and has a different pharmacology distinct from the Kv1.”
BackgroundPereira, L. E., Villinger, F., Wulff, H., Sankaranarayanan, A., Raman, G., & Ansari, A. A. (2007) · Experimental Biology and Medicine · doi:10.3181/0705-rm-148 · Cited by 48 · cited 3×
“3 inhibitors are ‘mild’ immunosuppressants and do not affect the ability of rodents or primates to clear bacterial or viral infections (Pereira et al., 2007; Matheu et al., 2008).”
BackgroundSelf-citationLam, D., & Schlichter, L. C. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00185 · Cited by 45 · cited 1×
“1 activity in microglial Ca 2 + signalling and migration under ‘resting’ and ‘anti-inflammatory states’ (Lam and Schlichter, 2015) and our own study showing that IL-4 induces large Kir2.”
BackgroundHoriuchi, M., Smith, L., Maezawa, I., & Jin, L.-W. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.02.014 · Cited by 43 · cited 1×
“RNA samples from acutely isolated microglia were further reverse-transcribed and pre-amplified as we previously described (Horiuchi et al., 2017).”
MethodSelf-citationCentral Nervous System: (Immunological) Ivory Tower or Not?
Marin, I. A., & Kipnis, J. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.122 · Cited by 39 · cited 1×
“3 channels can affect hippocampal synaptic plasticity and reduce amyloid deposition in APP/ PS1 mice are particularly interesting and support the po- tential of neuro-immunomodulation in treating neurodegen- erative disorders (Marin and Kipnis, 2017).”
BackgroundLinking T cells to Alzheimer's disease: from neurodegeneration to neurorepair
Bryson, K. J., & Lynch, M. A. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.10.003 · Cited by 36 · cited 1×
“Several groups also reported the presence of T cells in the brain of Alzheimer’s disease patients (Itagaki et al., 1988; Town et al., 2005; Bryson and Lynch, 2016).”
BackgroundThe Anti-Amyloid-β and Neuroprotective Properties of a Novel Tricyclic Pyrone Molecule
Maezawa, I., Zou, B., Lucente, J. D., Cao, W., Pascual, C., Weerasekara, S., Zhang, M., Xie, X., Hua, D. H., & Jin, L. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161175 · Cited by 14
Self-citationLam, D., & Schlichter, L. C. (2016) · Biophysical Journal · doi:10.1016/j.bpj.2015.11.1711 · Cited by 13
Cited by
Microglia polarization from M1 to M2 in neurodegenerative diseases
Guo, S., Wang, H., & Yin, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.815347 · Cited by 920
“3 is highly expressed in transgenic AD mouse models and AD patients’ brains (Maezawa et al., 2018).”
BackgroundRangaraju, S., Dammer, E. B., Raza, S. A., Rathakrishnan, P., Xiao, H., Gao, T., Duong, D. M., Pennington, M. W., Lah, J. J., Seyfried, N. T., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0254-8 · Cited by 430
“shown to have amyloid-lowering and neuroprotective effects in AD mouse models [26, 48, 49, 51, 62, 63].”
BackgroundSelf-citationRen, C., Li, D., Zhou, Q., & Hu, X. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119752 · Cited by 225
Cui, W., Sun, C., Ma, Y., Wang, S., Wang, X., & Zhang, Y. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00444 · Cited by 220
NLRP3-dependent pyroptosis is required for HIV-1 gp120-induced neuropathology
He, X., Yang, W., Zeng, Z., Wei, Y., Gao, J., Zhang, B., Li, L., Liu, L., Wan, Y., Zeng, Q., et al. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0260-y · Cited by 150
Metadata
- Authors
- Maezawa, I., Nguyen, H. M., Di Lucente, J., Jenkins, D. P., Singh, V., Hilt, S., Kim, K., Rangaraju, S., Levey, A. I., Wulff, H., & Jin, L.-W.
- Affiliations
- University of California Davis Medical Center (US)
- University of California, Davis (US)
- Department of Pathology and Laboratory Medicine, University of California Davis Medical Center, 2805 50th Street, Sacramento, CA 95817, USA
- Emory University (US)
- Corresponding author
- Maezawa, Izumi
- Wulff, Heike
- Jin, Lee-Way
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-12-18
- Volume
- 141
- Issue
- 2
- Pages
- 596-612
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC5837198
- OpenAlex
- W2780797805
- Cited by
- 125
- References
- 78
- Citations by year
- 2026: 9 · 2025: 15 · 2024: 15 · 2023: 15 · 2022: 17 · 2021: 24 · 2020: 14 · 2019: 7 · 2018: 9
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Brain (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- Kv1.3 potassium channel, Kir2.1, microglia, Alzheimer's disease, amyloid-beta oligomers, PAP1, microglial activation, macrophage polarization, neuroinflammation, cerebral amyloid deposition, APP/PS1 mice, hippocampal plasticity, microglia-targeted therapy
- MeSH terms
- Alzheimer Disease, Animals, Animals, Newborn, Avoidance Learning, Cells, Cultured, Disease Models, Animal, Exploratory Behavior, Ficusin, Gene Expression Regulation, Membrane Potentials, Mice, Inbred C57BL, Mice, Transgenic, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Microglia, Potassium Channel Blockers, Mice, Kv1.3 Potassium Channel, Shab Potassium Channels, Presenilin-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.